Related Experiment Videos
Is nebulized saline a placebo in COPD?
Shahina Y Khan1, B Ronan O'Driscoll
1Dept of Respiratory Medicine, Hope Hospital, Salford, M6 8HD UK. sykhan2001@yahoo.com
BMC Pulmonary Medicine
|October 2, 2004
Summary
Nebulized saline offers a clinical benefit for COPD patients by improving breathlessness and mucus expectoration, not just a placebo effect. Lung function remains unaffected by this treatment.
Area of Science:
- Respiratory Medicine
- Clinical Trials
Background:
- Nebulized saline is commonly used as a placebo in nebulized therapy trials.
- However, it may also have a clinical effect in managing symptoms for patients with Chronic Obstructive Pulmonary Disease (COPD).
Purpose of the Study:
- To determine if nebulized saline acts as a placebo or has a genuine clinical effect in COPD patients.
- Investigate its impact on breathlessness and sputum expectoration.
Main Methods:
- 40 hospitalized COPD patients with exacerbated disease were randomized.
- Patients received either active nebulized isotonic saline or placebo (inefficient nebulizer).
- Spirometry and breathlessness scores were measured pre- and post-treatment.
Main Results:
- No significant changes in lung function (FEV1) were observed with either active or placebo saline.
- Active nebulized saline significantly improved breathlessness (23%) and mucus expectoration (65% easier) compared to placebo (4% breathlessness improvement, 5% easier expectoration).
Conclusions:
- Nebulized saline provides a clinical benefit for COPD patients, likely by aiding sputum clearance and relieving breathlessness.
- It is suitable as a placebo in bronchodilator studies but not in trials evaluating symptom relief.